

Supplementary material

Supplementary Table 1 Patient selection.

	NER1006	%	OSS/2L PEG	%	Total n	% mFAS
Randomized full analysis set MORA	283		283			
Randomized full analysis set NOCT	310		311			
Total combined full analysis set	593	100%	594	100%	1187	
Primary analysis set mFAS MORA	275		272			
Primary analysis set mFAS NOCT	276		280			
Total primary analysis set mFAS	551	93%	552	93%	1103	100.0%
Patients with overall and right colon polyp and adenoma counts	513	87%	515	87%	1028	93.2%

OSS, oral sulfate solution; PEG, polyethylene glycol.

Supplementary Table 2. Patient characteristics at the screening visit.

	NER1006	OSS/2L PEG
Patients, N	513	515
Male, n (%)	241 (47.0)	283 (55.0)
Female, n (%)	272 (53.0)	232 (45.0)
Age, mean (SD)	56.9 (11.0)	55.5 (11.6)
BMI (kg/m ²), mean (SD)	28.5 (5.3); n = 508	28.1 (5.5); n = 508
Screening, n (%)	281 (54.8)	282 (54.8)
Surveillance, n (%)	140 (27.3)	138 (26.8)
Diagnostic, n (%)	92 (17.9)	95 (18.4)

OSS, oral sulfate solution; PEG, polyethylene glycol. BMI, body mass index.

Supplementary material

Supplementary Table 3 Male patient characteristics at the screening visit.

	All males		Males with BMI \geq 25	
	NER1006	OSS/2L PEG	NER1006	OSS/2L PEG
Patients, N	237	278	199	225
Males, (n%)	237 (100.0)	278 (100.0)	199 (100.0)	225 (100.0)
Age, mean (SD)	56.7 (11.3)	55.3 (11.9)	56.7 (11.3)	56.4 (10.6)
BMI (kg/m²), mean (SD)	29.1 (4.5)	28.9 (5.2)	30.2 (4.1)	30.2 (4.8)
Screening, n (%)	124 (52.3)	141 (50.7)	108 (54.3)	114 (50.7)
Surveillance, n (%)	68 (28.7)	81 (29.1)	55 (27.6)	69 (30.7)
Diagnostic, n (%)	45 (19.0)	56 (20.1)	36 (18.1)	42 (18.7)

BMI, body mass index; OSS, oral sulfate solution; PEG, polyethylene glycol.